Erratum to: Bayesian optimal interval designs for phase I clinical trials (Journal of the Royal Statistical Society: Series C (Applied Statistics), (2015), 64, 3, (507-523), 10.1111/rssc.12089);Bayesian optimal interval designs for phase I clinical trials

Journal of the Royal Statistical Society. Series C: Applied Statistics

Volumn 64, Issue 3, 2015, Pages 507-523

  Liu, Suyu ^a   Yuan, Ying ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Bayesian adaptive design; Decision error; Dose finding; Maximum tolerated dose

Indexed keywords

EID: 84924290324     PISSN: 00359254     EISSN: 14679876     Source Type: Journal    
DOI: 10.1111/rssc.12541     Document Type: Erratum

References (22)

1. Barlow, R. E., Bartholomew, D. J., Bremner, J. M. and Brunk, H. D. (1972) Statistical Inference under Order Restrictions. London: Wiley.
2. Cheung, Y. (2005) Coherence principles in dose-finding studies. Biometrika, 92, 863-873.
3. Chevret, S. (2006) Statistical Methods for Dose-finding Experiments. London: Wiley.
4. Durham, S. D. and Flournoy, N. (1994) Random walks for quantile estimation. In Statistical Decision Theory and Related Topics (eds J. O. Berger and S. S. Gupta ), pp. 467-476. New York: Springer.
5. Gerke, O. and Siedentop, H. (2008) Optimal phase I dose-escalation trial designs in oncology-a simulation study. Statist. Med., 27, 5329-5344.
6. Ivanova, A., Flournoy, N. and Chung, Y. (2007) Cumulative cohort design for dosefinding. J. Statist. Planng Inf., 137, 2316-2317.
7. Ivanova, A. and Kim, S. (2009) Dose-finding for binary ordinal and continuous outcomes with monotone objective function: a unified approach. Biometrics, 65, 307-315.
8. Jakacki, R. I., Hamilton, M., Gilbertson, J. R., Blaney, S. M., Tersak, J., Krailo, M. D., Ingle, A. M., Voss, S. D., Dancey, J. E. and Adamson, P. C. (2008) Pediatric phase I and pharmacokinetic study of erlotinib followed by the combination of erlotinib and temozolomide: a Childrens Oncology Group Phase I Consortium Study. J. Clin. Oncol., 26, 4921-4927.
9. Ji, Y., Liu, P., Li, Y. and Bekele, B. N. (2010) A modified toxicity probability interval method for dose-finding trials. Clin. Trials, 7, 653-663.
10. Korn, E. L., Midthune, D., Chen, T. T., Rubinstein, L. V., Christian, M. C. and Simon, R. M. (1994) A comparison of two phase I trial designs. Statist. Med., 13, 1799-1806.
11. Lee, S. and Cheung, Y. (2009) Model calibration in the continual reassessment method. Clin. Trials, 6, 227-238.
12. Lee, S. and Cheung, Y. (2011) Calibration of prior variance in the Bayesian continual reassessment method. Statist. Med., 30, 2081-2089.
13. Leung, D. and Wang, Y. G. (2001) Isotonic designs for phase I trials. Contr. Clin. Trials, 22, 126-138.
14. Lin, Y. and Shih, W. J. (2001) Statistical properties of the traditional algorithm-based designs for phase I cancer clinical trials. Biostatistics, 2, 203-215.
15. Neuenschwander, B., Branson, M. and Gsponer, T. (2008) Critical aspects of the Bayesian approach to phase I cancer trials. Statist. Med., 27, 2420-2439.
16. O'Quigley, J., Pepe, M. and Fisher, L. (1990) Continual reassessment method: a practical design for phase 1 clinical trials in cancer. Biometrics, 46, 33-48.
17. Oron, A., Azriel, D. and Hoff, P. (2011) Dose-finding designs: the role of convergence properties. Int. J. Biostatist., 7, article 39.
18. Paoletti, X., O'Quigley, J. and Maccario, J. (2004) Design efficiency in dose finding studies. Computnl Statist. Data Anal., 45, 197-214.
19. Storer, B. E. (1989) Design and analysis of phase I clinical trials. Biometrics, 45, 925-937.
20. Ting, N. (2006) Dose Finding in Drug Development. Berlin: Springer.
21. Whitehead, J. and Brunier, H. (1995) Bayesian decision procedures for dose determining experiments. Statist. Med., 14, 885-893.
22. Yuan, Z. and Chappell, R. (2004) Isotonic designs for phase I cancer clinical trials with multiple risk groups. Clin. Trials, 1, 499-508.